caa a22 4500 475803698 CHVBK 20180406123744.0 cr unu---uuuuu 170329e20001101xx s 000 0 eng 10.1007/s002680010213 doi (NATIONALLICENCE)springer-10.1007/s002680010213 Nuclear Medicine Applications for Neuroendocrine Tumors [Elektronische Daten] [J.F. Chatal, M.F. Le Bodic, F. Kraeber-Bodéré, C. Rousseau, I. Resche] Sensitive, specific radiopharmaceuticals are available for scintigraphic diagnosis and internal radiotherapy of neuroendocrine tumors. 123I-MIBG (metaiodobenzylguanidine) scintigraphy is the examination of choice for visualizing tumor sites of pheochromocytoma. In the event of malignant pheochromocytoma or carcinoid tumor, this examination allows assessment of the presence or absence of tumor uptake and can guide radiotherapy with 131I-MIBG. The peptides secreted by neuroendocrine tumors can be radiolabeled for targeting of their specific receptors. Scintigraphy using a 111In-labeled somatostatin analog (octreotide) is the examination of choice for diagnosis of the spread of gastroenteropancreatic and carcinoid tumors, as it is more sensitive than morphologic imaging techniques. It can also guide radiotherapy performed with the same pharmaceutical vector. These same two agents (MIBG and octreotide) can be used therapeutically by replacing 123I with 131I and 111In by 90Y. A transient palliative effect is obtained for a variable number of tumors (most often large ones) that take up the radiopharmaceutic agent well. There is general consensus that, for relatively radioresistant solid tumors, this type of radiotherapy is efficient only in the event of small tumor targets (a few millimeters in diameter) whose uptake is maximal, allowing more homogeneous distribution than that achieved with large tumors. Thus for optimal control of the disease it is recommended first to use scintigraphic imaging to confirm that the tumor takes up the radiopharmaceutical agent in question (123I-MIBG or 111In-octreotide) and then reduce the tumor burden surgically before injecting high therapeutic activity (possibly with reinjection of peripheral stem cells). This treatment can be repeated three times every 3 months before evaluating the response. In these conditions, internal radiotherapy can be beneficial or even determinant for controlling disease progression. Société Internationale de Chirurgie, 2000 Chatal J.F. Service de Médecine Nucléaire, Centre Régional de Lutte contre le Cancer René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR aut Le Bodic M.F. Service d'Anatomie Pathologique, C.H.U., Nantes-Saint Herblain, France, FR aut Kraeber-Bodéré F. Service de Médecine Nucléaire, Centre Régional de Lutte contre le Cancer René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR aut Rousseau C. Service de Médecine Nucléaire, Centre Régional de Lutte contre le Cancer René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR aut Resche I. Service de Médecine Nucléaire, Centre Régional de Lutte contre le Cancer René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR aut World Journal of Surgery Springer-Verlag 24/11(2000-11-01), 1285-1289 0364-2313 24:11<1285 2000 24 268 https://doi.org/10.1007/s002680010213 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002680010213 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Chatal J.F. Service de Médecine Nucléaire, Centre Régional de Lutte contre le Cancer René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR aut NATIONALLICENCE 700 1- Le Bodic M.F. Service d'Anatomie Pathologique, C.H.U., Nantes-Saint Herblain, France, FR aut NATIONALLICENCE 700 1- Kraeber-Bodéré F. Service de Médecine Nucléaire, Centre Régional de Lutte contre le Cancer René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR aut NATIONALLICENCE 700 1- Rousseau C. Service de Médecine Nucléaire, Centre Régional de Lutte contre le Cancer René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR aut NATIONALLICENCE 700 1- Resche I. Service de Médecine Nucléaire, Centre Régional de Lutte contre le Cancer René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR aut NATIONALLICENCE 773 0- World Journal of Surgery Springer-Verlag 24/11(2000-11-01), 1285-1289 0364-2313 24:11<1285 2000 24 268 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer